AIDS-related lymphoproliferative disease

Area of Science:

• Oncology
• Infectious Diseases
• Immunology

Background:

• Individuals with Human Immunodeficiency Virus (HIV) have a significantly higher incidence of lymphoma compared to the general population.
• AIDS-related lymphoma (ARL) predominantly presents as diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma, often with advanced extranodal disease and low CD4+ counts.
• Coinfections with Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) contribute to the development of rare lymphoma subtypes like plasmablastic and primary effusion lymphomas.

Purpose of the Study:

• To review the current understanding and management of AIDS-related lymphoma (ARL).
• To highlight advancements in ARL treatment, including the impact of highly active antiretroviral therapy (HAART).
• To discuss the role of hematopoietic-cell transplantation in relapsed ARL cases.

Main Methods:

• Review of recent clinical trials and evidence regarding ARL management.
• Analysis of treatment outcomes in HIV-infected individuals with lymphoma.
• Evaluation of the impact of HAART on ARL prognosis and opportunistic infections.

Main Results:

• Chemotherapy combined with HAART has led to improved outcomes for ARL.
• Hematopoietic-cell transplantation is a safe and effective salvage therapy for relapsed ARL.
• Opportunistic infections are less problematic with HAART, and its immunosuppressive effects appear transient.

Conclusions:

• Significant progress has been made in understanding and managing ARL.
• Despite improvements, outcomes for ARL remain inferior to those in HIV-negative individuals.
• Continued research and therapeutic advancements are necessary to further improve ARL patient survival.